Implantation of Mesenchymal Stem Cell, Conditioned Medium, or Triamcinolone Acetonide for Keloid Regression: Immunohistochemistry, Histopathology and Imaging Study

The clinical trial will be carried out at the Gatot Soebroto Army Central Hospital, Jakarta and planned from June 2020 to December 2020. Clinical trials of Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs) and Conditioned Medium Umbilical Cord-Mesenchymal Stem Cells (CM UC-MSCs) for Keloid were designed in three groups. Group 1 injected with The UC-MSCs at a dose of 2 million cells / cm3 using a 1 cc injection syringe (27G) by intra-lesion injection and booster with CM UC-MSCs at a dose of 1 cc / cm3 using a 1 cc injection syringe (27G) by intra-lesion injection and booster with CM UC-MSCs at the same dose 3 weeks later. Group 3 injected with Triamcinolon acetonide (TA) at a dose of 40 mg / cc / cm3 using 1 cc (27 G) syringe and booster with TA at 3 weeks later. The study subjects each group amounted to 7 patients suffering from Keloid. Patients were evaluated for 3 months after injection.

Start Date01 Sep 2020

Sponsor / Collaborator

PT Prodia Stemcell Indonesia

NCT04260698

/ CompletedPhase 3

An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.

Start Date08 Jul 2020

Sponsor / Collaborator

Gamida Cell Ltd.

NCT03173937

/ RecruitingPhase 1/2IIT

Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, to Expedite Engraftment and Improve Transplant Outcome

Background:
Severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS) are bone marrow diseases. People with these diseases usually need a bone marrow transplant. Researchers are testing ways to make stem cell transplant safer and more effective.
Objective:
To test if treating people with SAA or MDS with a co-infusion of blood stem cells from a family member and cord blood stem cells from an unrelated donor is safe and effective.
Eligibility:
Recipients ages 4-60 with SAA or MDS
Donors ages 4-75
Design:
Recipients will be screened with:
* Blood, lung, and heart tests
* Bone marrow biopsy
* CT scan
Recipients will have an IV line placed into a vein in the neck. Starting 11 days before the transplant they will have several chemotherapy infusions and 1 30-minute radiation dose.
Recipients will get the donor cells through the IV line. They will stay in the hospital 3-4 weeks. After discharge, they will have visits:
* First 3-4 months: 1-2 times weekly
* Then every 6 months for 5 years
Donors will be screened with:
* Physical exam
* Medical history
* Blood tests
Donors veins will be checked for suitability for stem cell collection. They may need an IV line to be placed in a thigh vein.
Donors will get Filgrastim or biosimilar (G-CSF) injections daily for 5-7 days. On the last day, they will have apheresis: Blood drawn from one arm or leg runs through a machine and into the other arm or leg. This may be repeated 2 days or 2-4 weeks later.
...

Start Date13 Jun 2017

Sponsor / Collaborator

National Heart, Lung & Blood Institute

100 Clinical Results associated with Omidubicel (Gamida Cell)

100 Translational Medicine associated with Omidubicel (Gamida Cell)

100 Patents (Medical) associated with Omidubicel (Gamida Cell)

Literatures (Medical) associated with Omidubicel (Gamida Cell)

01 Jan 2026·Stem Cell Reviews and Reports

Opening New Horizons: Advanced Hematopoietic Stem Cell Expansion Strategies Bridging Cord Blood Therapy from Bench To Bedside

Review

Author: Zhao, Yunyan ; Zhang, Yu ; Du, Wei ; Li, Guangzhao ; Liu, Rongzhi

Hematopoietic stem cell transplantation has been conducted in clinical settings to treat patients with malignant or non-malignant blood diseases for decades. Cord blood (CB) has been recognized as an essential graft source with beneficial characteristics, such as a lower risk of relapse and a lower rate of chronic graft-versus-host disease. However, the limited number of cells in CB impedes its broader use and hinders the ability to harness its benefits. Various expansion strategies have emerged to address this barrier, based on a deeper understanding of fate decisions and the maintenance of stemness in hematopoietic stem cells. To achieve an efficient transition from the laboratory to clinical application, several strategies have successfully managed scale-up manufacturing to satisfy clinically relevant requirements for both quality and scale. These approaches have progressed to the clinical stage and have demonstrated promising results. Novel expanded CB-derived hematopoietic stem and progenitor cells (HSPCs) therapies, including OMISIRGE (Omidubicel onlv.), Zemcelpro (Dorocubicel), and upcoming products with International Nonproprietary Name designations, introduce innovative concepts and comprehensive considerations for improving CB transplantation. This progress enables novel therapeutic options and represents a breakthrough in traditional CB transplants. In this context, we summarize and explore representative techniques and products to provide insights that inspire future developments in CB-derived HSPC therapies.

01 Aug 2025·Blood neoplasia

Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sources

Article

Author: He, Chujun ; Xu, Chunyi ; Burns, Linda J ; Tang, Xiao-Ying ; Sajeev, Gautam ; Zhang, Mei-Jie ; Horwitz, Mitchell E ; Simantov, Ronit ; Sivaraman, Smitha ; Signorovitch, James E ; Song, Yan ; Shin, Heayoung ; Lin, Chenyu

Omidubicel is a nicotinamide-expanded stem cell product derived from umbilical cord blood (UCB). In a phase 3 randomized trial for high-risk hematologic malignancies, omidubicel had faster neutrophil engraftment and fewer infectious complications than standard UCB transplantation. However, the clinical outcomes of omidubicel relative to other stem cell donor sources are yet to be determined. Clinical data for patients who underwent allogeneic hematopoietic cell transplantation (HCT) with omidubicel and standard UCB were taken from the phase 3 trial. The Center for International Blood and Marrow Transplant Research (CIBMTR) registry provided contemporaneous comparator cohorts of patients who met the trial eligibility criteria and who received allogeneic HCT from matched unrelated (MUD), mismatched unrelated (7/8 MMUD), and haploidentical donors. A total of 951 patients met the eligibility criteria, including 52 for omidubicel, 56 for standard UCB, 65 for 7/8 MMUD, 450 for MUD, and 328 for haploidentical donors. Omidubicel was associated with more rapid neutrophil engraftment than all other donor sources but slower platelet engraftment relative to other donor sources aside from UCB. There were no significant differences in overall survival, disease-free survival, and nonrelapse mortality among the donor sources. Omidubicel had a higher incidence of grade 2 to 4 acute graft-versus-host disease (GVHD), but similar rates of grade 3 to 4 acute GVHD and chronic GVHD compared to the CIBMTR cohorts. These results support the role of omidubicel as a viable donor source in the current transplant landscape.

01 Jul 2025·Transplantation and Cellular Therapy

Omidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access Program

Article

Author: Schiller, Gary J ; Rezvani, Andrew R ; Tsai, Stephanie B ; Levy, Stuart ; Mazor, Roei D ; Maziarz, Richard T ; Goshen, Uri ; Schwarzbach, Aurélie ; Stiff, Patrick J ; Horwitz, Mitchell E

Omidubicel-onlv is an FDA-approved, nicotinamide-modified, allogeneic hematopoietic progenitor cell therapy derived from umbilical cord blood (UCB). A phase 3 study demonstrated improved hematopoietic recovery and decreased infections with omidubicel compared with UCB allogeneic transplantation. We report results of an Expanded Access Program evaluating clinical outcomes in patients with hematologic malignancies following transplantation with omidubicel. Between August 2020 and May 2023, 29 patients were transplanted at 5 US sites. Patients received myeloablative conditioning, prophylactic and therapeutic medications, and supportive care per institutional guidelines, and were monitored for engraftment, infections, and graft-versus-host-disease (GVHD) for up to 2 years post-transplant. Results were compared with previously reported phase 3 outcomes. Omidubicel recipients had a median age of 39 (range 20-73, 62% male); 45% were non-White and 65.5% had acute leukemia. Median follow-up was 11.8 (range: .3-27.7) months. Median neutrophil and platelet engraftment times were 12 and 33.5 days, respectively. Acute GVHD (grade 3-4) at day 100 occurred in 19% of patients, with chronic GVHD at 1 year in 9% of patients, all of which were mild. First grade 2 to 3 bacterial infections through 100 days post-transplant and first grade 3 viral infection 1 year post-transplant occurred in 18% and 12% of patients, respectively. One-year disease-free survival and overall survival rates were 76% and 87%, respectively. This real-world study of omidubicel transplantation for hematologic malignancies finds that this graft source is commonly used for non-White allogeneic transplant recipients. The rapid engraftment kinetics observed following transplantation with omidubicel appears to have addressed excessive nonrelapse mortality that has been previously observed following myeloablative umbilical cord blood transplantation.

102

News (Medical) associated with Omidubicel (Gamida Cell)

09 Feb 2026

·www.biospace.com

Ayrmid Appoints ACA Pharma as Exclusive Distributor for Omisirge(R) across Greater China and Southeast Asia

ACA Pharma granted exclusive rights to register and distribute Omisirge across 15 markets, covering both FDA-approved Omisirge indications DUBLIN, IE / ACCESS Newswire / February 9, 2026 / Ayrmid, Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., today announced that it has appointed ACA Pharma as its exclusive distributor for Omisirge (Omidubicel-onlv) and granted ACA Pharma exclusive rights to seek registration and to distribute Omisirge across the following jurisdictions: Mainland China, Hong Kong SAR, Macau SAR, Mongolia, Brunei Darussalam, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam and Timor-Leste. Under the terms of the agreement, ACA Pharma will hold exclusive rights to register and distribute Omisirge across the Territory; the parties will prioritize specific jurisdictions for regulatory and launch planning based on local requirements and commercial considerations. Initial efforts may focus on lighthouse centers in Macau and Singapore, with additional jurisdictions assessed over time. Dr. Joe Wiley, CEO and Chairman of Ayrmidcommented: "This agreement represents continued progress as we expand access for patients in existing and new territories. Omisirge represents an important advancement in cell therapy and we look forward to working with the team at ACA as we continue to advance our innovative therapies to help patients with serious unmet medical needs." Mike Zhou, CEO of ACA Pharmacommented: "This appointment reflects a shared commitment to responsibly expanding access to Omisirge for appropriate patients across Greater China and Southeast Asia. ACA Pharma's platform is built for complex specialty products-combining regulatory execution, hospital launch capability, and end-to-end distribution-while maintaining the highest standards for quality and patient safety." About Omisirge Omisirge is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood. Omisirge is approved in the United States for: (1) adults and pediatric patients 12 years and older with hematologic malignancies planned for umbilical cord blood transplantation following myeloablative conditioning to reduce time to neutrophil recovery and incidence of infection; and (2) adults and pediatric patients 6 years of age and older with severe aplastic anemia following reduced-intensity conditioning. About Ayrmid Ltd. and Gamida Cell Ayrmid Ltd. is the parent company of Gamida Cell Inc., a pioneering cell therapy company developing novel treatments designed to turn cells into powerful therapeutics. Gamida Cell Inc. currently has two FDA approved products on the market in the US, namely Omisirge ® (please see the current full Prescribing Information, including boxed warning, here ) and APHEXDA ® (please see the current full Prescribing Information here ). Gamida Cell operates as a wholly owned subsidiary of Ayrmid Limited, a UK entity. For additional information, please visit or follow Gamida Cell on LinkedIn , X , Facebook or Instagram . Contacts: Media, Investors / Business Development: bd@ayrmid.com About ACA Pharma Founded in 1997, ACA Pharma is a U.S.-headquartered company specializing in fast-track registrations, early access programs, and end-to-end commercialization for innovative medicines and medical devices worldwide. The company is best known for its Macau Fast-Track platform for medicines and Hong Kong Fast-Track pathway for advanced devices, which can enable market entry in as little as 30-90 days in Macau and approximately three months in Hong Kong. These hubs then serve as launchpads to bridge into mainland China via the Greater Bay Area and other national pilot zones, with the real-world evidence generated supporting accelerated national approvals - particularly for products addressing unmet medical need, clinically urgent conditions, or rare diseases. Learn more at This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit . SOURCE: Ayrmid Pharma Ltd View the original press release on ACCESS Newswire

Cell TherapyLicense out/inDrug ApprovalClinical StudyAccelerated Approval

05 Feb 2026

·www.biospace.com

Ayrmid and Ariti Sign Distribution Agreement for Omisirge(R) in Greece and Cyprus

DUBLIN, IE / ACCESS Newswire / February 5, 2026 / Ayrmid, Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., today announced that it has entered into an exclusive distribution agreement with Ariti S.A., a Greece based pharmaceutical company for the distribution of Omisirge (Omidubicel-onlv) in Greece and Cyprus. Under the terms of the agreement, Ariti will provide services to support early access schemes to Omisirge in the agreed territories, leveraging its established expertise in hematology and local market infrastructure. Dr. Joe Wiley, Chief Executive Officer and Chairman of Ayrmidccommented: "This agreement represents continued progress as we expand access for patients in existing and new territories. We look forward to working with the team at Ariti and we remain deeply committed to advancing innovative therapies to help patients with serious unmet medical needs." Mr. Serafeim Kyrkos, Chief Executive Officer of Ariti S.A.commented: "This collaboration brings together our broad expertise in hematology with Ayrmid's innovative therapies, including Omisirge, the only FDA approved cell therapy for allogenic transplant for hematologic malignancies and for the treatment of Severe Aplastic Anemia. For both companies, this represents a tremendous opportunity to support market access in Greece and Cyprus, while driving mutual growth in the haemato-oncology segment". About Omisirge Omisirge is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood. Omisirge is approved in the United States for: (1) adults and pediatric patients 12 years and older with hematologic malignancies planned for umbilical cord blood transplantation following myeloablative conditioning to reduce time to neutrophil recovery and incidence of infection; and (2) adults and pediatric patients 6 years of age and older with severe aplastic anemia following reduced-intensity conditioning. About Ayrmid Ltd. and Gamida Cell Ayrmid Ltd. is the parent company of Gamida Cell Inc., a pioneering cell therapy company developing novel treatments designed to turn cells into powerful therapeutics. Gamida Cell Inc. currently has two FDA approved products on the market in the US, namely Omisirge ® (please see the current full Prescribing Information, including boxed warning, here ) and APHEXDA ® (please see the current full Prescribing Information here ). Gamida Cell operates as a wholly owned subsidiary of Ayrmid Limited, a UK entity. For additional information, please visit or follow Gamida Cell on LinkedIn , X , Facebook or Instagram . Contacts: Media, Investors / Business Development: bd@ayrmid.com About Ariti S.A. Ariti S.A., founded in 1985, is a well-established Greek healthcare company active in the pharmaceutical and medical sector. Over the past decades, the Company has built a strong track record in the exclusive representation, distribution and commercialization of pharmaceutical and healthcare products in Greece, in collaboration with reputable international partners. With extensive local expertise, Ariti leverages a solid commercial and regulatory infrastructure to support market access and broad product availability across Greece and Cyprus. Ariti also maintains an owned nationwide network of 10 chronic hemodialysis care units in Greece, strengthening its healthcare footprint and supporting its long-term commitment to improving patient outcomes. For additional information, please visit Ariti SA or follow Ariti SA on LinkedIn This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit . SOURCE: Ayrmid Pharma Ltd View the original press release on ACCESS Newswire

License out/inCell TherapyDrug ApprovalImmunotherapyBiosimilar

05 Feb 2026

·www.biospace.com

Ayrmid Pharma Ltd Announces Additional Positive Results for Omisirge(R) in Treating Severe Aplastic Anemia (SAA) Presented at TANDEM

Omisirge transplantation shows accelerated immune recovery in SAA New data presented at the 2026 TANDEM Meetings demonstrate that patients with SAA who received Omisirge experienced faster and more robust immune recovery compared with patients receiving alternative transplant graft sources Omisirge approved by FDA as First Cell Therapy to Treat Severe Aplastic Anemia Key Highlights of Data Presented at TANDEM: Rapid neutrophil recovery: Median time to neutrophil engraftment was 10 days following Omisirge transplantation. Faster recovery was associated with higher transplanted CD34⁺ cell doses Enhanced CD4⁺T-cell reconstitution: At six months post-transplant, CD4⁺ T-cell counts were significantly higher in Omisirge recipients compared with other transplant sources including matched and haploidentical donors. Higher CD4⁺ T-cell recovery correlated with more rapid neutrophil engraftment Accelerated NK-cell recovery: Natural killer (NK) cell reconstitution occurred early after transplant, with median NK-cell counts at days 30 and 100 exceeding those observed across all comparator graft sources Omisirge approved by the FDA on December 5, 2025 for SAA DUBLIN, IE / ACCESS Newswire / February 5, 2026 / Ayrmid Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., a leader in cell therapy innovation, today announced further positive interim clinical results for Omisirge (Omidubicel-onlv), its advanced stem cell transplant therapy for Severe Aplastic Anemia (SAA). The data showed that patients with SAA who received Omisirge transplants experienced faster and more robust immune recovery compared with patients receiving other transplant graft sources, including HLA-matched donor peripheral blood stem cells, haploidentical donors with post-transplant cyclophosphamide, standard cord blood, and combined cord/haploidentical transplants. The findings come from an ongoing single-center Phase II study conducted at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) and were presented by investigators from NHLBI/NIH and collaborating institutions at the 2026 Transplantation & Cellular Therapy meetings of ASTCT ® and CIBMTR ® (TANDEM), taking place from February 4-7, 2026 in Salt Lake City, UT. Alternative donor hematopoietic cell transplantation (HCT) has historically been limited in SAA by delayed engraftment and high rates of graft rejection. Omisirge is a nicotinamide-expanded cord blood product designed to increase the number of hematopoietic stem and progenitor cells available for transplantation. Dr. Richard Childs of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH) commented: "In this study, we observed that Omisirge transplantation was associated with faster neutrophil engraftment and earlier recovery of key immune cell populations compared with historical transplant approaches in SAA. These findings suggest that enhanced stem cell dose may translate into improved early immune reconstitution in this high-risk patient population." Dr. Ronit Simantov, Chief Medical and Scientific Officer of Ayrmid commented: "These results highlight the significant potential of Omisirge as a transplant option for patients with SAA. The enhanced immune recovery observed following Omisirge transplantation may have important clinical implications for patients with SAA, including improved engraftment, reduced risk of graft rejection, and potentially lower susceptibility to infections in the post-transplant period. We remain deeply committed to advancing transformative therapies for patients with serious unmet medical needs." Omisirge is now approved for treatment in adults and pediatric patients 6 years of age and older with SAA following reduced intensity conditioning. The FDA approval of Omisirge was based on data from the 17-H-0091 study. About Severe Aplastic Anemia Severe Aplastic Anemia is a rare, life-threatening hematologic disorder in which the bone marrow fails to produce sufficient blood cells. Stem cell transplantation offers a potential cure; however, many patients lack a matched sibling donor. Ayrmid is advancing therapies to address this unmet medical need. About Ayrmid Ltd. and Gamida Cell Ayrmid Ltd. is the parent company of Gamida Cell Inc., a pioneering cell therapy company developing novel treatments designed to turn cells into powerful therapeutics. Gamida Cell Inc. currently has two FDA approved products on the market in the US, namely Omisirge ® (please see the current full Prescribing Information, including boxed warning, here ) and APHEXDA ® (please see the current full Prescribing Information here ). Gamida Cell operates as a wholly owned subsidiary of Ayrmid Limited, a UK entity. For additional information, please visit or follow Gamida Cell on LinkedIn , X , Facebook or Instagram . Contacts: Media, Investors / Business Development: bd@ayrmid.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit . SOURCE: Ayrmid Pharma Ltd View the original press release on ACCESS Newswire

Clinical ResultCell TherapyImmunotherapyPhase 2Drug Approval

100 Deals associated with Omidubicel (Gamida Cell)

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anemia, Aplastic	United States	Gamida Cell Ltd.	08 Dec 2025
Hematologic Neoplasms	United States	Gamida Cell Ltd.	17 Apr 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
acute leukemia	Phase 3	United States	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	Brazil	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	France	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	Israel	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	Italy	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	Netherlands	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	Portugal	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	Singapore	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	Spain	Gamida Cell Ltd.	16 Dec 2016
acute leukemia	Phase 3	United Kingdom	Gamida Cell Ltd.	16 Dec 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Graft vs Host Disease	18	Omidubicel	bcgqbvfyix(irqtxalhdz) = ovgnkwaikf ldncquporr (nnfuuqzqdo ) View more	Positive	04 Feb 2026
				Omidubicel	usbabgcofd(aiooxlucfd) = kjkrqzjthm fzmfuacghe (rxgxogxgqb ) View more
BusinessWire Manual	Phase 1	Anemia, Aplastic	14	Omidubicel	opslgeocal(sabedgsfhc) = howlzeqtdd qlnbfcikgm (dyhjmfafxf ) View more	Positive	28 Oct 2025
NCT02730299 (Tandem Meetings ASTCT and CIBMTR2024) Manual	Phase 3	Hematologic Neoplasms	-	Omidubicel (EAP)	njrauokggm(yufazdnoju) = loqtsnfufh cbiuqgmnbh (fjzwrgmtnz ) View more	Positive	22 Feb 2024
				omidubicel (P3-OMI)	njrauokggm(yufazdnoju) = mlspsvgzcg cbiuqgmnbh (fjzwrgmtnz ) View more
NCT02730299 (Pubmed \| Transplant Cell Ther)	Phase 3	Hematologic Neoplasms	108	Omidubicel-onlv	sjtiykqiqu(yrotusxqco) = izzfiufxav mycwmeiecj (lzxfraasif ) View more	Positive	01 Dec 2023
				Umbilical Cord Blood Transplantation	sjtiykqiqu(yrotusxqco) = yghkbyrdob mycwmeiecj (lzxfraasif ) View more
NCT02730299 (Phase 3 Substudy, Pubmed \| Transplant Cell Ther)	Phase 3	Graft Rejection	37	Omidubicel	vkanerszkt(hzqxndnyto) = pngivoaeuf hpyxqoumlx (agyewvfbtx ) View more	Positive	01 Aug 2023
				Omidubicel (Standard UCB)	dvjztzgbfl(unxnmmtoyf) = gkoestxpyl zsixbomnee (uinpuwhnvl )
NCT02730299 (FDA) Manual	Phase 3	Hematologic Neoplasms	125	OMISIRGE	wzvszmhagr(xgfrlowhvz) = sfqfbzhlrs cbxgxnhnmx (oresrivzxc, 10 - 15) View more	Superior	17 Apr 2023
				Umbilical Cord Blood	wzvszmhagr(xgfrlowhvz) = zsatqahayt cbxgxnhnmx (oresrivzxc, 19 - 25) View more
SOHO2022	Phase 3	Hematopoietic stem cell transplantation	116	Omidubicel	hsoenczbvi(jijxaxhyld) = mxylcosfys ihtobmgdbp (yexawcsrzu, 47.0–67.1) View more	Positive	01 Oct 2022
phase III trial (SOHO2022)	Phase 3	Hematopoietic stem cell transplantation	108	Omidubicel	vetecnpkhs(mnmmuhkrce) = uzvcsciayn jdrapwyldt (joxbbshozs, p = 0.04) View more	Positive	01 Oct 2022
Phase III Randomized, Multicenter Study (Tandem Meetings ASTCT and CIBMTR2022)	Phase 3	-	125	Omidubicel	imsfagogmx(iukjohqqsv) = klbokuqpdk lyowmqlwxc (efkozpnwly, -10% - 23%) View more	Positive	01 Mar 2022
				Omidubicel (Standard Myeloablative Umbilical Cord Blood Transplantation (UCBT))	imsfagogmx(iukjohqqsv) = olkobxbqno lyowmqlwxc (efkozpnwly ) View more
NCT02730299 (phase III, Tandem Meetings ASTCT and CIBMTR2022)	Phase 3	Hematologic Neoplasms	-	Omidubicel	rxneyjdinn(irizlbvand) = jwjiukupmw voybyqlxvt (gkncjnbcwq ) View more	Positive	01 Mar 2022
				Omidubicel (Umbilical Cord Blood (UCB))	rxneyjdinn(irizlbvand) = iiojxycllp voybyqlxvt (gkncjnbcwq ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Omidubicel (Gamida Cell)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation